Treatment of PSC in Children with Features of Autoimmune Hepatitis (Autoimmune Sclerosing Cholangitis)
Primary sclerosing cholangitis (PSC) in pediatric patients who also present features of autoimmune hepatitis represents a distinct clinical variant — autoimmune sclerosing cholangitis — that calls for a tailored management approach.
Clinical scenario
Children (age under 18) with PSC who show features of autoimmune hepatitis, consistent with the autoimmune sclerosing cholangitis variant syndrome.
Treatment overview
A response to immunosuppressive therapy has been documented in children with this variant syndrome, pointing to this class of treatment as relevant for eligible pediatric patients. The complete regimen and decision pathway are detailed in the full protocol.
References
DOI: 10.1016/j.jhep.2022.05.011
However, a response to immunosuppressive therapy has been documented in children with autoimmune hepatitis/sclerosing cholangitis variant syndrome (also called autoimmune sclerosing cholangitis).
View source ↗